Molecular characterization of the role of orphan receptor small heterodimer partner in development of fatty liver

Hepatology

Volumn 46, Issue 1, 2007, Pages 147-157

  Huang, Jiansheng ^a   Iqbal, Jahangir ^b   Saha, Pradip K ^c   Liu, Jun ^c   Chan, Lawrence ^c   Hussain, M Mahmood ^b   Moore, David D ^c   Wang, Li ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; GONADORELIN; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; FATTY LIVER; GENOTYPE; INSULIN SENSITIVITY; LIPID TRANSPORT; LIPOGENESIS; LIVER CELL; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL;

ADIPOSE TISSUE, BROWN; ANIMALS; BIOLOGICAL TRANSPORT; CELLS, CULTURED; FATTY LIVER; GENE DELETION; HEPATOCYTES; LEPTIN; LIPIDS; MICE; MICE, INBRED C57BL; MICE, OBESE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA;

EID: 34547411540     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21632     Document Type: Article

References (47)

1. Sarafidis PA, Nilsson PM. The metabolic syndrome: a glance at its history. J Hypertens 2006;24:621-626.
2. Choudhury J, Sanyal AJ. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis 2004;8:575-594.
3. Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005;16:421-427.
4. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijarvi A, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002;87:3023-3028.
5. Kelley DE, McKolanis TM, Hegazi RA, Kuller LH, Kalhan SC. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 2003;285:E906-E916.
6. Day CP. The potential role of genes in nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8:673-691.
7. Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, Leclercq I. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. HEPATOLOGY 2003;38:123-132.
8. Letteron P, Sutton A, Mansouri A, Fromenty B, Pessayre D. Inhibition of microsomal triglyceride Transfer protein: another mechanism for drug-induced steatosis in mice. HEPATOLOGY 2003;38:133-140.
9. Di Leo E, Lancellotti S, Penacchioni JY, Cefalu AB, Averna M, Pisciotta L, et al. Mutations in MTP gene in abeta- and hypobeta-lipoproteinemia. Atherosclerosis 2005;180:311-318.
10. Namikawa C, Shu-Ping Z, Vyselaar JR, Nozaki Y, Nemoto Y, Ono M, et al. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J Hepatol 2004;40:781-786.
11. Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR, et al. Liver peroxisome proliferator-activated receptor contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 2003;278:34268-34276.
12. Seol W, Choi HS, Moore DD. An orphan nuclear hormone receptor that lacks a DNA binding domain and heterodimerizes with other receptors. Science 1996;272:1336-1339.
13. Bavner A, Sanyal S, Gustafsson JA, Treuter E. Transcriptional corepression by SHP: molecular mechanisms and physiological consequences. Trends Endocrinol Metab 2005;16:478-488.
14. Wang L, Lee YK, Bundman D, Han Y, Thevananther S, Kim CS, et al. Redundant pathways for negative feedback regulation of bile acid production. Dev Cell 2002;2:721-731.
15. Wang L, Han Y, Kim CS, Lee YK, Moore DD. Resistance of SHP-null mice to bile acid induced liver damage. J Biol Chem 2003;278:44475-44481.
16. Boulias K, Katrakili N, Bamberg K, Underhill P, Greenfield A, Talianidis I. Regulation of hepatic metabolic pathways by the orphan nuclear receptor SHP. EMBO J 2005;24:2624-2633.
17. Wang L, Liu J, Saha P, Huang JS, Chan L, Spiegelman B, et al. The orphan nuclear receptor SHP regulates PGC-1α expression and energy production in brown adipocytes. Cell Metab 2005;2:227-238.
18. Wang L, Huang JS, Saha P, Kulkarni RN, Hu M, Kim YD, et al. Nuclear receptor SHP is an important mediator of glucose homeostasis. Mol Endocrinol 2006;20:2671-2681.
19. Schadinger SE, Bucher NL, Schreiber BM, Farmer SR. PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes. Am J Physiol Endocrinol Metab 2005;288:E1195-E1205.
20. Wolfrum C, Stoffel M. Coactivation of Foxa2 through Pgc-1beta promotes liver fatty acid oxidation and triglyceride/VLDL secretion. Cell Metab 2006;3:99-110.
21. Athar H, Iqbal J, Jiang, XC, Hussain MM. A simple, rapid, and sensitive fluorescence assay for microsomal triglyceride transfer protein. J Lipid Res 2004;45:764-772.
22. Li X, Grundy SM, Patel SB. Obesity in db and ob animals leads to impaired hepatic very low density lipoprotein secretion and differential secretion of apolipoprotein B-48 and B-100. J Lipid Res 1997;38:1277-1288.
23. Camus MC, Aubert R, Bourgeois F, Herzog J, Alexiu A, Lemonnier D. Serum lipoprotein and apolipoprotein profiles of the genetically obese ob/ob mouse. Biochim Biophys Acta 1988;961:53-64.
24. Battels ED, Lautitsen M, Nielsen LB. Hepatic expression of microsomal triglyceride transfer protein and in vivo secretion of triglyceride-rich lipoproteins are increased in obese diabetic mice. Diabetes 2002;51:1233-1239.
25. Wiegman CH, Bandsma RH, Ouwens M, van der Sluijs FH, Havinga R, Boer T, et. al. Hepatic VLDL production in ob/ob mice is not stimulated by massive de novo lipogenesis but is less sensitive to the suppressive effects of insulin. Diabetes 2003;52:1081-1089.
26. Homanics GE, de Silva HV, Osada J, Zhang SH, Wong H, Borensztajn J, et al. Mild dyslipidemia in mice following Targeted inactivation of the hepatic lipase gene. J Biol Chem 1995;270:2974-2980.
27. Shih DQ, Bussen M, Sehayek E, Ananthanarayanan M, Shneider BL, Suchy FJ, et al. Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism. Nat Genet 2001;27:375-382.
28. Gruen ML, Plummer MR, Zhang W, Posey KA, Linton MF, Fazio S, et al. Persistence of high density lipoprotein particles in obese mice lacking apolipoprotein A-I. J Lip Res 2005;46:2007-2014.
29. Sirvent A, Verhoeven AJ, Jansen H, Kosykh V, Darteil RJ, Hum DW, et al. Farnesoid X receptor represses hepatic lipase gene expression. J Lipid Res 2004;45:2110-2115.
30. Thuren T. Hepatic lipase and HDL metabolism. Curr Opin Lipidol 2000;11:277-283.
31. Ma K, Cilingiroglu M, Otvos JD, Ballantyne CM, Marian AJ, Chan L. Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. Proc Natl Acad Sci U S A 2003;100:2748-2753.
32. Hussain MM, Shi J, Dreizen P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J Lipid Res 2003;44:22-32.
33. Swift LL, Zhu MY, Kakkad B, Jovanovska A, Neely MD, Valyi-Nagy K, et al. Subcellular localization of microsomal triglyceride transfer protein. J Lipid Res 2003;44:1841-1849.
34. Hirokane H, Nakahara M, Tachibana S, Shimizu M, Sato R. Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4. J Biol Chem 2004;279:45685-45692.
35. Wetterau JR, Lin MC, Jamil H. Microsomal triglyceride Microsomal triglyceride transfer protein. Biochim Biophys Acta 1997;1345:136-50. Review.
36. Bakillah A, El Abbouyi A. The role of microsomal triglyceride transfer protein in lipoprotein assembly: an update. Front Biosci 2003;8:d294-305.
37. Lee YK, Dell H, Dowhan DH, Hadzopoulou-Cladaras M, Moore DD. The orphan nuclear receptor SHP inhibits hepatocyte nuclear factor 4 and retinoid X receptor transactivation: two mechanisms for repression. Mol Cell Biol 2000;20:187-195.
38. Yu S, Matsusue K, Kashireddy P, Cao WQ, Yeldandi V, Yeldandi AV, et al. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gammal (PPAR-gamma1) overexpression. J Biol Chem 2003;278:498-505.
39. Nishizawa H, Yamagata K, Shimomura I, Takahashi M, Kuriyama H, Kishida K, et al. Small heterodimer partner, an orphan nuclear receptor, augments peroxisome proliferator-activated receptor gamma transactivation. J Biol Chem 2002;277:1586-1592.
40. Watanable M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004;113:1408-1418.
41. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A 2006;103:1006-1011.
42. Ma K, Saha PK, Chan L, Moore DD. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006;116:1102-1109.
43. den Boer M, Voshol PJ, Kuipers F, Havekes LM, Romijn JA. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler Thromb Vasc Biol 2004;24:644-649. Review.
44. Koteish A, Diehl AM. Animal models of steatosis. Semin Liver Dis 2001;21:89-104. Review.
45. Silver DL, Wang N, Tall AR. Defective HDL particle uptake in ob/ob hepatocytes causes decreased recycling, degradation, and selective lipid uptake. J Clin Invest 2000;105:151-159.
46. Nishina PM, Naggert JK, Verstuyft J, Paigen B. Atherosclerosis in genetically obese mice: the mutants obese, diabetes, fat, tubby, and lethal yellow. Metabolism 1994;43:554-558.
47. Wolfrum C, Poy MN, Stoffel M. Apolipoprotein M is required for pre-beta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med 2005;11:418-422.